Geleen, Netherlands
Geleen, Netherlands

DSM is a Dutch-based multinational life science and materials science company. DSM's global end markets include food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM has annual net sales of around €10 billion and employs some 24,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. The company is listed on NYSE Euronext. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

The European nutraceuticals market is projected to grow at a rate of 5.9%, with France leading the market. The region is the third largest market for nutraceuticals in the world, after North America and Asia- Pacific. The market has a demand for advanced nutraceutical products, which can provide visible benefits on consumption. The reason for the European market growth being restrained is its stringent regulatory approval procedures and high-cost of research and product development, which, in turn, increases the price of the products. Algal-based omega-3 fatty acids and natural plant extracts are the new trend in the nutraceutical market; omega3 is one of the most consumed nutraceuticals, due to its association with many disease prevention and treatments, such as thrombosis, atherosclerosis, cancers, arthritis, etc. Many global players in functional food and beverages are now trying to invest in algal-based omega-3 fatty acids (EPA and DHA) production and supply in the European Market. The European nutraceuticals market is competitive with many market giants, such as ADM, DuPont, Cargill, Inc., Royal DSM, and BASF SE. These large players are holding the majority of the nutraceuticals market share in Europe. These market giants are trying to increase their market through various market strategies, such as nutraceutical innovation, technological advancement, partnership, mergers, acquisition, market expansion and categories expansion. For more information about this report visit http://www.researchandmarkets.com/research/bpz2zd/europe Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/europe-nutraceutical-market---growth-trends--forecasts-to-2022---expected-to-grow-at-a-cagr-of-59---research-and-markets-300456310.html


This report studies Pet Food Nutraceutical in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Kemin Vit2be-Diana Group Symrise BASF Roquette Freres Royal DSM Dupont Darling International Inc Archer Daniels Midland Nestle (Purina PetCare) The Scoular Company Omega Protein Merial Novotech neutraceutical Nutraceuticals International Proctor & Gamble (Mars) By types, the market can be split into Milk Bio Actives Omega 3 Fatty Acids Probiotics Proteins and Peptides Dietary Fiber Others By Application, the market can be split into Dogs Cats Bird Fish Others By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global Pet Food Nutraceutical Market Professional Survey Report 2017 1 Industry Overview of Pet Food Nutraceutical 1.1 Definition and Specifications of Pet Food Nutraceutical 1.1.1 Definition of Pet Food Nutraceutical 1.1.2 Specifications of Pet Food Nutraceutical 1.2 Classification of Pet Food Nutraceutical 1.2.1 Milk Bio Actives 1.2.2 Omega 3 Fatty Acids 1.2.3 Probiotics 1.2.4 Proteins and Peptides 1.2.5 Dietary Fiber 1.2.6 Others 1.3 Applications of Pet Food Nutraceutical 1.3.1 Dogs 1.3.2 Cats 1.3.3 Bird 1.3.4 Fish 1.3.5 Others 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 2 Manufacturing Cost Structure Analysis of Pet Food Nutraceutical 2.1 Raw Material and Suppliers 2.2 Manufacturing Cost Structure Analysis of Pet Food Nutraceutical 2.3 Manufacturing Process Analysis of Pet Food Nutraceutical 2.4 Industry Chain Structure of Pet Food Nutraceutical 8 Major Manufacturers Analysis of Pet Food Nutraceutical 8.1 Kemin 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Product A 8.1.2.2 Product B 8.1.3 Kemin 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Kemin 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.2 Vit2be-Diana Group 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Product A 8.2.2.2 Product B 8.2.3 Vit2be-Diana Group 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 Vit2be-Diana Group 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.3 Symrise 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Product A 8.3.2.2 Product B 8.3.3 Symrise 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Symrise 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.4 BASF 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Product A 8.4.2.2 Product B 8.4.3 BASF 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 BASF 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.5 Roquette Freres 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Product A 8.5.2.2 Product B 8.5.3 Roquette Freres 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 Roquette Freres 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.6 Royal DSM 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Product A 8.6.2.2 Product B 8.6.3 Royal DSM 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 Royal DSM 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.7 Dupont 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Product A 8.7.2.2 Product B 8.7.3 Dupont 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Dupont 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.8 Darling International Inc 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Product A 8.8.2.2 Product B 8.8.3 Darling International Inc 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Darling International Inc 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.9 Archer Daniels Midland 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Product A 8.9.2.2 Product B 8.9.3 Archer Daniels Midland 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Archer Daniels Midland 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.10 Nestle (Purina PetCare) 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Product A 8.10.2.2 Product B 8.10.3 Nestle (Purina PetCare) 2016 Pet Food Nutraceutical Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Nestle (Purina PetCare) 2016 Pet Food Nutraceutical Business Region Distribution Analysis 8.11 The Scoular Company 8.12 Omega Protein 8.13 Merial 8.14 Novotech neutraceutical 8.15 Nutraceuticals International 8.16 Proctor & Gamble (Mars) For more information, please visit https://www.wiseguyreports.com/sample-request/1272620-global-pet-food-nutraceutical-market-professional-survey-report-2017


EMERYVILLE, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it expects revenue related to its Vitamin E partnership with Nenter to more than double based on the current success of the program. During 2016, the company shipped approximately $9 million of farnesene to Nenter for conversion to Vitamin E and expects 2017 shipments to Nenter to be about $20 million. Success with Nenter on Vitamin E Amyris and Nenter have a strong partnership and commitment to grow together, supplying high performing Vitamin E oil to the global nutraceuticals market. The commercialization phase of this  partnership has started very strong and is an exclusive commitment between the two companies for the commercial production of Vitamin E. Exclusive License Agreement with DSM on Vitamin A The company also announced today that as part of its focus on growing its relationship with Koninklijke DSM N.V. (Royal DSM)(AEX:DSM.AS) it is entering into an exclusive licensing agreement for Vitamin A within the nutraceuticals market. This relationship is focused on a fast-track to market for the production and commercialization of low-cost supply of Vitamin A. “Nenter’s investment and commitment to the Vitamin E market has proved to be an ideal partnership for growth by both companies,” said John Melo, Amyris President & CEO. “We are excited by their early commercialization results. This is a great example of combining our technology platform with their capabilities to deliver better chemistry. We plan to replicate this success with DSM on Vitamin A and expect a successful program and delivery of product before the end of 2019.” About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com. Amyris Forward-Looking Statements This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the company’s anticipated 2017 Vitamin E-related sales to Nenter, its expectations regarding entering into an exclusive licensing agreement for Vitamin A with Royal DSM within the nutraceuticals market with fast-track to market for the production and commercialization of the product with low-cost supply, and the company’s belief that it will be able to provide delivery of Vitamin A to Royal DSM before the end of 2019) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.


EMERYVILLE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the closing of the first tranche of up to $95 million in planned equity financing that the company previously announced on May 8, 2017. The first tranche, which closed today, was approximately $47 million and was led by Koninklijke DSM N.V. (Royal DSM) (AEX:DSM.AS) with participation by qualified institutional buyers and accredited investors, including some which have previously engaged in equity and/or debt investments in Amyris. Subject to the satisfaction of certain conditions and approval by DSM's Managing Board, DSM may invest an additional $25 million in Amyris within 90 days of the closing of the first tranche. Amyris has commitments from current, long term investors that exceeds the remaining $23 million to meet the company’s $95 million objective. As part of a development cooperation with DSM, the two parties have agreed to focus on a number of short- to medium-term product development & production opportunities in vitamins and other nutritional ingredients. Amyris noted that as the companies successfully engage in these activities the revenue and margin will be accretive to Amyris’s current revenue plan. Use of Cash for Debt Reduction Amyris noted that of approximately $75 million in debt that it is in the process of reducing that the majority has already converted or is expected to be converted in the relative near term. As a result, outside of these conversions to reduce debt, the company expects to deploy less than $20 million of total cash raised to pay down the aggregate debt amount of $75 million. About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com. Amyris Forward-Looking Statements This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected closing of a second tranche of financing, including the size and timing thereof, anticipated future revenue and margin resulting from the development cooperation with DSM, and expected debt reduction, including the amount, timing and form thereof) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.


EMERYVILLE, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it expects revenue related to its Vitamin E partnership with Nenter to more than double based on the current success of the program. During 2016, the company shipped approximately $9 million of farnesene to Nenter for conversion to Vitamin E and expects 2017 shipments to Nenter to be about $20 million. Success with Nenter on Vitamin E Amyris and Nenter have a strong partnership and commitment to grow together, supplying high performing Vitamin E oil to the global nutraceuticals market. The commercialization phase of this  partnership has started very strong and is an exclusive commitment between the two companies for the commercial production of Vitamin E. Exclusive License Agreement with DSM on Vitamin A The company also announced today that as part of its focus on growing its relationship with Koninklijke DSM N.V. (Royal DSM)(AEX:DSM.AS) it is entering into an exclusive licensing agreement for Vitamin A within the nutraceuticals market. This relationship is focused on a fast-track to market for the production and commercialization of low-cost supply of Vitamin A. “Nenter’s investment and commitment to the Vitamin E market has proved to be an ideal partnership for growth by both companies,” said John Melo, Amyris President & CEO. “We are excited by their early commercialization results. This is a great example of combining our technology platform with their capabilities to deliver better chemistry. We plan to replicate this success with DSM on Vitamin A and expect a successful program and delivery of product before the end of 2019.” About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com. Amyris Forward-Looking Statements This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the company’s anticipated 2017 Vitamin E-related sales to Nenter, its expectations regarding entering into an exclusive licensing agreement for Vitamin A with Royal DSM within the nutraceuticals market with fast-track to market for the production and commercialization of the product with low-cost supply, and the company’s belief that it will be able to provide delivery of Vitamin A to Royal DSM before the end of 2019) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.


News Article | May 10, 2017
Site: marketersmedia.com

— Growing demand for fiber supplements to overcome nutrition deficiency and increasing health consciousness among the people are the drivers propelling the market growth. Moreover change in life style requires more fiber nutrients to balance the diet is another prominent factor driving the market growth. However stringent regulatory approvals are hindering the market growth. Insoluble fiber in product segment is anticipated to move with a highest CAGR during forecast period owing to maintenance of balanced PH by consuming these kinds of fibers. Fruits and vegetables in source segment accounted for the largest market share in 2015, cereals and grains segment is expected to show healthy growth rate during forecast period. North America accounted for the highest market share as compared to other regions. The Asia Pacific region is expected to grow at a higher CAGR and is anticipated to account for the highest market share during forecast period owing to increase in disposable incomes. Some of the key players in the market include Archer Daniels Midland Company (ADM), Cargill, Incorporated, Danisco, E. I. Dupont De Nemours and Company, GlaxosmithKline(GSK), Grain Processing Corporation, Ingredion Incorporated, J. Rettenmaier & Söhne GmbH & Co. Kg, Novartis, Novus International, Procter and Gamble, Roquette Frères Company, Royal DSM, Sas Nexira, Südzucker AG Company, Sunopta, Inc. And Tate & Lyle PLC Company. Products Covered: • Soluble o Pectin o Inulin o Beta-Glucan o Polydextrose o Other Solubles • Conventional • Insoluble o Resistant Starch o Lignin o Chitin o Chitosan o Hemicellulose o Cellulose o Other Insoluble • Novel Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


EMERYVILLE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the closing of the first tranche of up to $95 million in planned equity financing that the company previously announced on May 8, 2017. The first tranche, which closed today, was approximately $47 million and was led by Koninklijke DSM N.V. (Royal DSM) (AEX:DSM.AS) with participation by qualified institutional buyers and accredited investors, including some which have previously engaged in equity and/or debt investments in Amyris. Subject to the satisfaction of certain conditions and approval by DSM's Managing Board, DSM may invest an additional $25 million in Amyris within 90 days of the closing of the first tranche. Amyris has commitments from current, long term investors that exceeds the remaining $23 million to meet the company’s $95 million objective. As part of a development cooperation with DSM, the two parties have agreed to focus on a number of short- to medium-term product development & production opportunities in vitamins and other nutritional ingredients. Amyris noted that as the companies successfully engage in these activities the revenue and margin will be accretive to Amyris’s current revenue plan. Use of Cash for Debt Reduction Amyris noted that of approximately $75 million in debt that it is in the process of reducing that the majority has already converted or is expected to be converted in the relative near term. As a result, outside of these conversions to reduce debt, the company expects to deploy less than $20 million of total cash raised to pay down the aggregate debt amount of $75 million. About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com. Amyris Forward-Looking Statements This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected closing of a second tranche of financing, including the size and timing thereof, anticipated future revenue and margin resulting from the development cooperation with DSM, and expected debt reduction, including the amount, timing and form thereof) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.


Ager D.J.,DSM Innovative Synthesis BV | De Vries A.H.M.,Royal DSM | De Vries J.G.,Royal DSM
Chemical Society Reviews | Year: 2012

Asymmetric hydrogenations are increasingly being used to introduce stereogenic centres into products used in the life sciences industries. There are a number of potential pitfalls when moving from a laboratory reaction to a manufacturing process, not least of which is safety. Time-to-market pressure leads to short development times, which in the past could be a large barrier for the implementation of catalytic steps; now there are new ways to minimise this problem. The potential problems associated with impurities and other methods that can shut down the hydrogenation reactions are highlighted in this critical review (353 references). © 2012 The Royal Society of Chemistry.


De Vries J.G.,Royal DSM
Topics in Organometallic Chemistry | Year: 2012

Palladium-catalysed coupling reactions have gained importance as a tool for the production of pharmaceutical intermediates and to a lesser extent also for the production of agrochemicals, flavours and fragrances, and monomers for polymers. In this review only these cases are discussed where it seems highly likely that the technology is or has been used for ton-scale production. We document twelve cases where the Mizoroki-Heck reaction was used to arylate an alkene. In two of these cases allylic alcohols were arylated, leading to the aldehyde or the ketone. The Suzuki reaction has been used mostly to produce biaryl compounds from aryl halides and arylboronic acid derivatives. Twelve processes were recorded. Ortho-tolyl-benzonitrile, a biaryl compound produced via the Suzuki reaction, is used as an intermediate in six different pharmaceuticals all belonging to the Sartan group of blood pressure-lowering agents. The Kumada-Corriu reaction in which an aryl or alkenyl Grignard is coupled to an aryl or alkenyl halide was used nine times. In these coupling reactions palladium is often replaced by the much cheaper nickel or iron catalysts. The Negishi reaction couples an arylzinc halide with an aryl or alkenyl halide. These reactions are fast and highly selective; the only drawback being the stoichiometric zinc waste. Two cases were found. In one of these it was possible to use only a catalytic amount of zinc (double metal catalysis). The Sonogashira reaction couples a terminal alkyne to an aryl or alkenyl halide. Three cases were found. Acetylene is usually not coupled as such in view of its instability. Instead, trimethylsilylacetylene or the acetylene acetone adduct is used. Finally, one case was found of a palladium-catalysed allylic substitution and one case of a CH-activation reaction to form a benzocyclobutane ring. Most of these reactions were implemented in production in the past ten years. © 2012 Springer-Verlag Berlin Heidelberg.


Sagt C.M.J.,Royal DSM
Applied Microbiology and Biotechnology | Year: 2013

Systems metabolic engineering is based on systems biology, synthetic biology, and evolutionary engineering and is now also applied in industry. Industrial use of systems metabolic engineering focuses on strain and process optimization. Since ambitious yields, titers, productivities, and low costs are key in an industrial setting, the use of effective and robust methods in systems metabolic engineering is becoming very important. Major improvements in the field of proteomics and metabolomics have been crucial in the development of genome-wide approaches in strain and process development. This is accompanied by a rapid increase in DNA sequencing and synthesis capacity. These developments enable the use of systems metabolic engineering in an industrial setting. Industrial systems metabolic engineering can be defined as the combined use of genome-wide genomics, transcriptomics, proteomics, and metabolomics to modify strains or processes. This approach has become very common since the technology for generating large data sets of all levels of the cellular processes has developed quite fast into robust, reliable, and affordable methods. The main challenge and scope of this mini review is how to translate these large data sets in relevant biological leads which can be tested for strain or process improvements. Experimental setup, heterogeneity of the culture, and sample pretreatment are important issues which are easily underrated. In addition, the process of structuring, filtering, and visualization of data is important, but also, the availability of a genetic toolbox and equipment for medium/high-throughput fermentation is a key success factor. For an efficient bioprocess, all the different components in this process have to work together. Therefore, mutual tuning of these components is an important strategy. © 2013 Springer-Verlag Berlin Heidelberg.

Loading Royal DSM collaborators
Loading Royal DSM collaborators